KALRAY
13.6.2019 18:02:06 CEST | Business Wire | Press release
Kalray (Euronext Growth Paris: ALKAL), a pioneer in processors for new intelligent systems, is delighted to announce that the company will be a key technology provider and partner of the European Processor Initiative (EPI) with its MPPA® cluster (“Massively Parallel Processor Array”) technology. In particular, on account of its expertise and unique technology, Kalray will lead the acceleration technology work for the automotive version of the next generation EPI processor.
Kalray will team up with key industrial players such as Atos-Bull, BMW Group and Infineon to achieve high performance and deterministic automotive computation, together with reduced power consumption.
The EPI, officially launched in December 2018, with 26 participating companies and organizations from 10 European countries, is a crucial element of the European Exascale strategy. The project is funded under the European Union’s Horizon 2020, a €77bn research and innovation program for 2014-2020, aimed at securing Europe's global competitiveness, driving economic growth and creating jobs.
The EPI aims to create a family of low-power high compute processors, embedding ARM Limited’s CPU as the mainstream General Purpose Processor, as well as dedicated accelerator technologies. Initial designs are for supercomputers. Next in line are Europe's car makers, which hope to adopt these powerful new chips.
In the project, Kalray will develop its IP offering by providing the MPPA® Cluster IP (as an Hardware IP Block) and integrating it with the mainstream ARM CPU. Kalray will also participate in the hardware and software architecture definition, and in the implementation and integration into the next generations of automotive systems, along with the other automotive partners of the initiative, such as BMW Group, Infineon or Elektrobit.
Eric Baissus, CEO of Kalray : “I am delighted for the selection of Kalray’s MPPA® Manycore technology for the European Processor Initiative. The EPI processors will embed the MPPA® Cluster IP along with the latest ARM advanced CPUs. In addition to participating in a very exciting European project, this is a great opportunity for Kalray to extend the market reach of our technology in the coming years.”
ABOUT EPI
The European Processor Initiative (EPI) is a project currently implemented under the first stage of the Framework Partnership Agreement signed by the Consortium with the European Commission (FPA: 800928), whose aim is to design and implement a roadmap for a new family of low-power European processors for extreme scale computing, high-performance Big-Data and a range of emerging applications.
The list of participating partners and all other relevant information on EPI can be found at: www.european-processor-initiative.eu
ABOUT KALRAY
Kalray (Euronext Growth Paris — FR0010722819 — ALKAL) is the pioneer in processors for new intelligent systems. As a real technological breakthrough, “intelligent” processors have the capability to analyze on the fly, and in an intelligent manner, a very large amount of information, and to make decisions and interact in real time with the outside world. These intelligent processors will be deployed extensively in fast-growing sectors, such as new-generation networks (intelligent data centers) and autonomous vehicles, as well as healthcare equipment, drones, and robots. Kalray’s offering encompasses both processors and complete solutions (electronic boards and software). Created in 2008 as a spin-off of CEA (“Commissariat à l'énergie atomique et aux énergies alternatives”, the French Alternative Energies and Atomic Energy Commission), Kalray serves customers such as server manufacturers, intelligent system integrators, and consumer product manufacturers, including car makers. For more information, visit www.kalrayinc.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190613005558/en/
Contact:
CONTACTS INVESTISSEURS Eric BAISSUS contactinvestisseurs@kalray.eu Tel. 04 76 18 90 71
ACTUS finance & communication Caroline LESAGE kalray@actus.fr Tel. 01 53 67 36 79
CONTACTS PRESSE Loic HAMON communication@kalray.eu Tel. 04 76 18 90 71
ACTUS finance & communication Serena BONI sboni@actus.fr Tel. 04 72 18 04 92
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ARIS Announced as Exclusive Process Intelligence Launch Partner for AWS European Sovereign Cloud8.6.2026 09:00:00 CEST | Press release
Partnership Will Enable Enterprises to Accelerate AI Adoption While Ensuring Digital Sovereignty ARIS, the process context foundation for enterprise AI deployment, today announced its collaboration with Amazon Web Services (AWS) to support organizations navigating increasingly complex digital sovereignty requirements while accelerating AI-driven transformation. Many European enterprises face growing pressure to ensure sensitive operational and business data remains under European governance and regulatory control. Through the AWS European Sovereign Cloud (ESC), they will be able to combine advanced cloud and AI capabilities with enhanced operational separation, EU-based governance, and strict data residency controls. ARIS will support customers looking to operationalize AI safely and at scale within these boundaries by providing the process intelligence, governance, and operational context required for trusted enterprise AI deployment. “AI is moving rapidly from experimentation to oper
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom